(February 20, 2018) – Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application for INBRIJA. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of October 5, 2018. Read more…